checkAd
    Startseite > Aktien > Sarepta Therapeutics > Nachrichten
    Sarepta Therapeutics Aktie
    123,46
     
    USD
    -2,89 %
    -3,67 USD
    Letzter Kurs 25.05.24 Nasdaq
    123,43
     
    USD
    1.200 STK
    Geldkurs 24.05.24
    123,46
     
    USD
    500 STK
    Briefkurs 24.05.24
    ISIN: US8036071004 · WKN: A1J1BH · SYM: SRPT · USA

    Neueste Nachrichten

    Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health
    03.05.24 · Business Wire (engl.) · Sarepta Therapeutics
    Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments
    01.05.24 · Business Wire (engl.) · Sarepta Therapeutics
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    01.05.24 · Business Wire (engl.) · Sarepta Therapeutics
    Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
    24.04.24 · Business Wire (engl.) · Sarepta Therapeutics
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    29.03.24 · Business Wire (engl.) · Sarepta Therapeutics
    Sarepta Therapeutics to Present at Upcoming Investor Conferences
    04.03.24 · Business Wire (engl.) · Sarepta Therapeutics
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    01.03.24 · Business Wire (engl.) · Sarepta Therapeutics
    Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program
    29.02.24 · Business Wire (engl.) · Sarepta Therapeutics
    Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments
    28.02.24 · Business Wire (engl.) · Sarepta Therapeutics
    Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
    21.02.24 · Business Wire (engl.) · Sarepta Therapeutics
    Fokus Aktien mit extremen Handelsvolumen am Montag, den 19.02.2024
    19.02.24 · wO Chartvergleich · AMETEK
    Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication
    16.02.24 · Business Wire (engl.) · Sarepta Therapeutics